Literature DB >> 16613340

E-cadherin status in breast cancer correlates with histologic type but does not correlate with established prognostic parameters.

Hina S Qureshi1, Michael D Linden, George Divine, Usha B Raju.   

Abstract

Our objective was to assess the loss of E-cadherin (EC) as a diagnostic marker or a predictor of prognosis. We stained 276 breast carcinomas with monoclonal antibodies to EC (invasive lobular carcinomas [ILC] and variants, 59; invasive ductal carcinoma and ductal special types [IDC], 204; tubulolobular carcinoma [TLC], 4; and invasive carcinoma [IC], uncertain whether lobular or ductal type, 9). The results were as follows: EC+IDCs, 99.5%; EC-ILCs, 90%; EC+ILCs, 10%; EC+pleomorphic ILCs, 20%; EC-ICs, 44%. All 4 TLCs showed positive tubules while cords were negative. Statistically a correlation of EC loss with a positive diagnosis of ILC was found but there was no correlation with any prognostic tumor variables. A negative EC stain confirms the diagnosis of ILC (specificity, 97.7%; negative predictive value, 96.8%; sensitivity, 88.1%; positive predictive value, 91.2%). EC is helpful in classifying cases with indeterminate histologic features. EC loss is uncommon in nonlobular carcinomas with no correlation to currently established prognostic variables.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16613340

Source DB:  PubMed          Journal:  Am J Clin Pathol        ISSN: 0002-9173            Impact factor:   2.493


  20 in total

Review 1.  Management of locally advanced breast cancer-perspectives and future directions.

Authors:  Konstantinos Tryfonidis; Elzbieta Senkus; Maria J Cardoso; Fatima Cardoso
Journal:  Nat Rev Clin Oncol       Date:  2015-02-10       Impact factor: 66.675

2.  [Warthin tumor with carcinoma: malignant transformation or metastasis?].

Authors:  D Baumhoer; M Pfaltz; J Seydoux; G Jundt
Journal:  Pathologe       Date:  2009-11       Impact factor: 1.011

3.  ΔNp63α Promotes Breast Cancer Cell Motility through the Selective Activation of Components of the Epithelial-to-Mesenchymal Transition Program.

Authors:  Tuyen T Dang; Matthew A Esparza; Erin A Maine; Jill M Westcott; Gray W Pearson
Journal:  Cancer Res       Date:  2015-08-19       Impact factor: 12.701

4.  A new Ki-67 / E-cadherin cocktail reduces inter-observer variation of the calculated proliferative index.

Authors:  Golan Bubis; Ohad Hilly; Roy Bubis; Marisa Halpern; Ariel Schwartz; Rumelia Koren; Lea Rath-Wolfson
Journal:  Pathol Oncol Res       Date:  2013-07-07       Impact factor: 3.201

Review 5.  American Registry of Pathology Expert Opinions: The Spectrum of Lobular Carcinoma in Situ: Diagnostic Features and Clinical Implications.

Authors:  Stuart J Schnitt; Edi Brogi; Yunn-Yi Chen; Tari A King; Sunil R Lakhani
Journal:  Ann Diagn Pathol       Date:  2020-02-15       Impact factor: 2.090

Review 6.  [Lobular neoplasms and invasive lobular breast cancer].

Authors:  H-P Sinn; B Helmchen; J Heil; S Aulmann
Journal:  Pathologe       Date:  2014-02       Impact factor: 1.011

7.  Nuclear localization of Kaiso promotes the poorly differentiated phenotype and EMT in infiltrating ductal carcinomas.

Authors:  Jacqueline Jones; Honghe Wang; Balasubramanyam Karanam; Shaniece Theodore; Windy Dean-Colomb; Danny R Welch; William Grizzle; Clayton Yates
Journal:  Clin Exp Metastasis       Date:  2014-02-26       Impact factor: 5.150

8.  Germline E-cadherin mutations in familial lobular breast cancer.

Authors:  S Masciari; N Larsson; J Senz; N Boyd; P Kaurah; M J Kandel; L N Harris; H C Pinheiro; A Troussard; P Miron; N Tung; C Oliveira; L Collins; S Schnitt; J E Garber; D Huntsman
Journal:  J Med Genet       Date:  2007-07-27       Impact factor: 6.318

9.  Cadherin and integrin regulation of epithelial cell migration.

Authors:  Jonathan Silvestre; Paul J A Kenis; Deborah E Leckband
Journal:  Langmuir       Date:  2009-09-01       Impact factor: 3.882

10.  Expression analysis of E-cadherin, Slug and GSK3beta in invasive ductal carcinoma of breast.

Authors:  Chandra P Prasad; Gayatri Rath; Sandeep Mathur; Dinesh Bhatnagar; Rajinder Parshad; Ranju Ralhan
Journal:  BMC Cancer       Date:  2009-09-14       Impact factor: 4.430

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.